Recommendation based on Phase III PROVENT trial showing a significant reduction in the risk of developing symptomatic COVID-19, with protection lasting at least six months
The FDA decision is primarily informed by the positive results of a proof-of-concept, Phase 2a study evaluating the safety, immunogenicity, and efficacy of a single dose of 120µg RSVpreF in a human viral challenge model in healthy adults 18 to 50 years of age
The accelerated use of technology in clinical trials and the shift towards virtual trials is here to stay
#BeTheChangeForTB is a public awareness initiative under the Corporate TB Pledge and aims to create a cadre of Youth Changemakers who can act as catalysts of change to help eliminate TB from India
It is the fourth vaccine to get the nod for 12 years and older after Biological E’s Corbevax, Bharat Biotech’s Covaxin and Zydus Lifesciences Zy-CoV-D
The first-of-its-kind unique centre will increase access to preventive & primary care
The expansion makes Exothera one of the largest viral vector facilities in Europe
Augnito in association with Japanese company Fujifilm enables voice recognition within their radiology information system platform
Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab
The system boasts features that help streamline processes in the SPD and OR and reduce the possibility of wet sets.
Subscribe To Our Newsletter & Stay Updated
